Hahn Gustavo Drügg, Golovics Petra Anna, Wetwittayakhlang Panu, Al Khoury Alex, Bessissow Talat, Lakatos Peter Laszlo
Division of Gastroenterology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada.
School of Medicine, Graduate Course Sciences in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-002, Brazil.
Biomedicines. 2022 Mar 23;10(4):749. doi: 10.3390/biomedicines10040749.
Inflammatory bowel disease (IBD) is a chronic, life-long inflammatory condition of the gastrointestinal tract. Treatment strategy depends on the severity of the disease course. IBD physicians need to be aware of the life-long treatment options available. The goal is not only to achieve clinical remission but to halt or stabilize the chronic inflammation in the intestines to prevent further structural damage. Therefore, the use of early biologic therapy is recommended in moderate-to-severe IBD patients. However, in the last decade, use of therapeutic drug monitoring has increased considerably, opening an opportunity for sequencing. This review summarizes the available evidence on biologic and small molecules therapy in Crohn's disease (CD) and ulcerative colitis (UC) in different clinical scenarios, including perianal CD, the elderly, extra intestinal manifestations, and pregnancy.
炎症性肠病（IBD）是一种胃肠道的慢性、终身性炎症性疾病。治疗策略取决于疾病进程的严重程度。IBD医生需要了解现有的终身治疗方案。目标不仅是实现临床缓解，还要阻止或稳定肠道中的慢性炎症，以防止进一步的结构损伤。因此，建议在中重度IBD患者中早期使用生物疗法。然而，在过去十年中，治疗药物监测的使用显著增加，为序贯治疗提供了机会。本综述总结了在不同临床场景下，包括肛周克罗恩病、老年患者、肠外表现和妊娠等情况下，生物制剂和小分子药物治疗克罗恩病（CD）和溃疡性结肠炎（UC）的现有证据。
